Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Leukemia

  Free Subscription


27.10.2025

1 Am J Hematol
3 Ann Hematol
6 Blood
1 BMC Cancer
1 Bone Marrow Transplant
2 Cancer
1 Eur J Haematol
1 Leuk Lymphoma
1 Leuk Res
2 Leukemia
1 PLoS One


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. KIRTEK TJ, Chen W, Harris JC, Bagg A, et al
    Acute Leukemias of Ambiguous Lineage With RUNX1 Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With RUNX1 Mutations: A Study From the Bone Marrow Pathology Group.
    Am J Hematol. 2025 Oct 18. doi: 10.1002/ajh.70116.
    PubMed         Abstract available


    Ann Hematol

  2. SUO T, Zhang J, Chen Y, Shi H, et al
    ResNet50 and Single-Cell Multi-Omics analysis identify key cellular and molecular features in pediatric acute lymphoblastic leukemia.
    Ann Hematol. 2025 Oct 23. doi: 10.1007/s00277-025-06675.
    PubMed         Abstract available

  3. ZHU L, Yi K, Zhou J, Hu G, et al
    Concurrent NPM1::CCDC28A and BCR::ABL1 fusions in extramedullary blast crisis of chronic myeloid leukemia: A case report and literature review.
    Ann Hematol. 2025 Oct 22. doi: 10.1007/s00277-025-06680.
    PubMed         Abstract available

  4. ZHENG J, Wang Y, Li Z, Xiao P, et al
    Frequent TCR rearrangements in pediatric B-cell lymphoblastic acute leukemia: genomic and phenotypic features.
    Ann Hematol. 2025 Oct 20. doi: 10.1007/s00277-025-06687.
    PubMed         Abstract available


    Blood

  5. SHI Y, Jiang Q, Li L, Zuo Y, et al
    Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1.
    Blood. 2025;146:2088-2101.
    PubMed         Abstract available

  6. DUNCAVAGE E, Spencer D
    Leukemic fusion: partners and mutations shape NUP98r leukemia.
    Blood. 2025;146:2017-2018.
    PubMed        

  7. LASZIG S, Diederichs A, Salzmann-Manrique E, Schuschel K, et al
    CPX-351 in Down syndrome-associated Myeloid Leukemia: Results and Prognostic Factors from the Phase 3 ML-DS 2018 Trial.
    Blood. 2025 Oct 21:blood.2025030775. doi: 10.1182/blood.2025030775.
    PubMed         Abstract available

  8. LAM K, Kim YJ, Tan EL, Ong CM, et al
    The Proteostasis Network is a Therapeutic Target in Acute Myeloid Leukemia.
    Blood. 2025 Oct 20:blood.2024026749. doi: 10.1182/blood.2024026749.
    PubMed         Abstract available

  9. THAKUR RK, Karlsson G
    Insights from Single-cell Omics: Cellular Heterogeneity as a Foundation of Clinical Outcome in Chronic Myeloid Leukemia.
    Blood. 2025 Oct 17:blood.2025029011. doi: 10.1182/blood.2025029011.
    PubMed         Abstract available

  10. SHADMAN M, Davids MS
    How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor.
    Blood. 2025;146:2029-2036.
    PubMed         Abstract available


    BMC Cancer

  11. GRAMATGES MM, Sanclemente LN, Hall L, Taylor OA, et al
    A multicenter observational cohort study in survivors of Down Syndrome-associated acute leukemia (ALTE22C1): a report from the Children's Oncology Group.
    BMC Cancer. 2025;25:1611.
    PubMed         Abstract available


    Bone Marrow Transplant

  12. NAGLER A, Galimard JE, Kayser S, Kulagin A, et al
    Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2025 Oct 18. doi: 10.1038/s41409-025-02726.
    PubMed         Abstract available


    Cancer

  13. KANTARJIAN HM, Borthakur G, Daver N, DiNardo C, et al
    A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens.
    Cancer. 2025;131:e70113.
    PubMed         Abstract available

  14. PEIPERT JD, Ganatra S, Zhao F, Lee JW, et al
    Overall side-effect bother consistently associated with early treatment discontinuation due to adverse events in four clinical trials with various cancer types and treatments.
    Cancer. 2025;131 Suppl 2.
    PubMed         Abstract available


    Eur J Haematol

  15. OLIVA S, Molica S
    Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.
    Eur J Haematol. 2025 Oct 21. doi: 10.1111/ejh.70047.
    PubMed         Abstract available


    Leuk Lymphoma

  16. ARANI N, Rausch CR, Geppner A, Borthakur G, et al
    Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Oct 22:1-5. doi: 10.1080/10428194.2025.2566318.
    PubMed        


    Leuk Res

  17. LEI Y, Tang Z, Reese JA, Jamy O, et al
    The role of interim bone marrow assessments in acute myeloid leukemia - A systematic review and meta-analysis.
    Leuk Res. 2025;159:108121.
    PubMed         Abstract available


    Leukemia

  18. VU TT, Stolzel F, Wang KW, Rollig C, et al
    Correction: miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
    Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02788.
    PubMed        

  19. GOODMAN SJ, Butcher DT, Guger SL, Diehl E, et al
    DNA methylation alterations in acute lymphoblastic leukemia survivors with late neurocognitive deficits.
    Leukemia. 2025 Oct 17. doi: 10.1038/s41375-025-02779.
    PubMed        


    PLoS One

  20. MOHAMED A, Giudice L, Basilio J, Barresi S, et al
    Germinal center trajectories and transcriptional signatures define CLL subtypes and their pathway regulators.
    PLoS One. 2025;20:e0335069.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.